Latest News for: stat6
Edit
The Eagle-Tribune
12 Jun 2026
Recludix Pharma to Present Preclinical Asthma and Dermatitis Data for Oral STAT6 Inhibitor
Edit
Recludix Pharma to Present Preclinical Asthma and Dermatitis Data for Oral STAT6 Inhibitor REX-8756 at ...
Nasdaq Globe Newswire 12 Jun 2026
Edit
Caledonian Record
15 May 2026
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader,
Late-breaking presentation at SID and featured presentation at the ATS Respiratory Innovation Summit highlight KT-621 BroADen Phase 1b clinical data and potential across Type 2 inflammatory diseases ....
Edit
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for ...
Nasdaq Globe Newswire 15 May 2026
Late-breaking presentation at SID and featured presentation at the ATS Respiratory Innovation Summit highlight KT-621 BroADen Phase 1b clinical data and potential across Type 2 inflammatory diseases ... .
Edit
The Eagle-Tribune
04 May 2026
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at ...
Edit
Recludix Pharma Announces Upcoming Oral Presentations on Preclinical Data for Oral STAT6 Inhibitor REX-8756 and ...
Nasdaq Globe Newswire 04 May 2026
Edit
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
Pharmiweb 04 May 2026
Edit
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader ...
Nasdaq Globe Newswire 13 Apr 2026
Edit
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma (Kymera Therapeutics Inc)
Public Technologies 13 Apr 2026
Food and Drug Administration (FDA) has granted Fast Track designation to KT-621, its first-in-class oral STAT6 degrader, for the treatment of moderate to severe eosinophilic asthma.
- 1